EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open access · CC BY-NC 4.0

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial

Messoud Ashina iD, Stewart J Tepper, Uwe Reuter, Andrew M Blumenfeld, Susan Hutchinson iD, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M Trugman

Headache: The Journal of Head and Face Pain · 2023-01 · 63 (1) · 79-88

DOI: 10.1111/head.14439 ↗

At a glance

Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, published online on 2023-01-18. Written by Messoud Ashina and 9 co-authors. Institution: Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen…. Major MEDLINE topics: Migraine Disorders. Cited 59 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AbbVie.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

To assess long‐term safety, tolerability, and efficacy of once‐daily oral atogepant 60 mg in adults with migraine.

Background

Atogepant is an oral, small‐molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of episodic migraine.

Methods

A 52‐week, multicenter, randomized, open‐label trial of adults (18–80 years) with migraine. Lead‐in trial completers or newly enrolled participants with 4–14 migraine days/month were enrolled and randomized (5:2) to atogepant 60 mg once daily or oral standard care (SC) migraine preventive medication. The primary objective was to evaluate the safety and tolerability of atogepant; safety assessments included treatment‐emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, and Columbia‐Suicide Severity Rating Scale scores. Efficacy assessments (atogepant only) included change from baseline in mean monthly migraine days (MMDs) and the proportion of participants with reductions from baseline of ≥50%, ≥75%, and 100% in MMDs.

Results

The trial included 744 participants randomized to atogepant 60 mg ( n = 546) or SC ( n = 198). The atogepant safety population was 88.2% female ( n = 479/543) with a mean (standard deviation) age of 42.5 (12.0) years. TEAEs occurred in 67.0% ( n = 364/543) of participants treated with atogepant 60 mg. The most commonly reported TEAEs (≥5%) were upper respiratory tract infection (10.3%; 56/543), constipation (7.2%; 39/543), nausea (6.3%; 34/543), and urinary tract infection (5.2%; 28/543). Serious TEAEs were reported in 4.4% (24/543) for atogepant. Mean (standard error) change in MMDs for atogepant was −3.8 (0.1) for weeks 1–4 and −5.2 (0.2) at weeks 49–52. Similarly, the proportion of participants with ≥50%, ≥75%, and 100% reductions in MMDs increased from 60.4% (310/513), 37.2% (191/513), and 20.7% (106/513) at weeks 1–4 to 84.2% (282/335), 69.9% (234/335), and 48.4% (162/335), at weeks 49–52.

Conclusion

Daily use of oral atogepant 60 mg for preventive treatment of migraine during this 1‐year, open‐label trial was safe, well tolerated, and efficacious.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersAdultHumansFemaleMaleTreatment OutcomeDouble-Blind MethodNauseaPiperidinesPyridinesPyrrolesSpiro Compounds

Author keywords

atogepantcalcitonin gene-related peptidegepantmigrainemigraine preventive

Substances

atogepantPiperidinesPyridinesPyrrolesSpiro Compounds

Authors and institutions

  • Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Headache Center of Southern California, Carlsbad, California, USA.
  • Orange County Migraine and Headache Center, Irvine, California, USA.
  • AbbVie, Madison, New Jersey, USA.

ORCID profiles: Messoud Ashina, Susan Hutchinson

Funding

  • AbbVie

Cite

APA

Ashina, M., Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache: The Journal of Head and Face Pain, 63(1), 79-88. https://doi.org/10.1111/head.14439

Vancouver

Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, et al. Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache: The Journal of Head and Face Pain. 2023;63(1):79-88. doi:10.1111/head.14439

BibTeX
@article{Ashina2023,
  author = {Ashina, Messoud and Tepper, Stewart J and Reuter, Uwe and Blumenfeld, Andrew M and Hutchinson, Susan and Xia, Jing and Miceli, Rosa and Severt, Lawrence and Finnegan, Michelle and Trugman, Joel M},
  title = {Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  volume = {63},
  number = {1},
  pages = {79--88},
  doi = {10.1111/head.14439}
}
Start for free →